Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p181 | (1) | ICCBH2015

Short stature in osteogenesis imperfecta: consider alternative diagnoses

Steele Caroline , Sultan Wajid , Bishop Nick , Ehtisham Sarah

Background: A 15 year old boy with antenatally diagnosed osteogenesis imperfecta (OI) was reviewed following concerns about poor linear growth, lack of pubertal development and persistent deciduous teeth. He had a history of crush fractures of L1–L2 and previous intra-medullary rodding of his right femur and had been on oral bisphosphonates (Risedronate 70 mg once weekly). He was significantly short (height SDS −4.9), substantially below his genetic potential (targe...

ba0005p20 | Biochemical testing | ECTS2016

Frozen for 7 years: How long can bones be stored prior to biomechanical testing?

Varela Aurore , Smith Susan

Biomechanical strength testing of bones, considered a key component in bone quality assessment, is a critical end-point in the evaluation of safety and efficacy of test compounds in preclinical studies. Bones are usually preserved frozen and tested within a few months following harvesting. They can also be stored for longer periods and only tested when additional information is required. The objective of this study was to evaluate if differences in biomechanics data between di...

ba0006is17 | (1) (1) | ICCBH2017

Factors influencing peak bone mass

Harvey Nicholas C

Peak bone mass is a major determinant of osteoporosis risk and subsequent fragility fractures in older age. There is a wide range of factors influencing peak bone mass, ranging from those acting very early in life, for example in utero and periconception, to those acting through childhood and adolescence into young adulthood. In this presentation I will give an overview of some overarching themes and principles of relevance to peak bone mass, using specific clinical scenarios ...

ba0006oc13 | (1) | ICCBH2017

Enterococccus faecium abundance in gut microbiome is associated with higher bone mineral density in school age children

Medina-Gomez Carolina , Radjabzadeh Djawad , Boer Cindy G. , Van Meurs Joyce , Kraaij Robert , Uitterlinden Andre G , Rivadeneira Fernando

Aim: Human gut microbiota is an important determinant of health and disease. Discoveries from recent microbiome studies have been postulated as actionable targets to treat malnutrition, diabetes, obesity among other conditions. The role of the gut microbiome on the development of the human musculoskeletal system is yet to be established. The aim of our study was to investigate the association between bacterial operational taxonomic units (OTUs) of the gut in relation to bone m...

ba0006p032 | (1) | ICCBH2017

Bone health status in Indian children with type 1 diabetes as assessed by peripheral quantitative computer tomography (pQCT)

Mandlik Rubina , Ekbote Veena , Bhor Shital , Kajale Neha , Pawar Jwala , Narwade Shriram , Khadilkar Vaman , Chiplonkar Shashi , Padidela Raja , Mughal Zulf , Khadilkar Anuradha

Objective: Our earlier study using dual energy x-ray absorptiometry had shown that longer duration of type 1 diabetes (T1DM) in children was associated with small and slender bones. The objective of this study was to assess bone geometry in children and adolescents with T1DM using a pQCT.Methods: We studied 69 children (8.3 to 18.7 years of age, 29 boys) with T1DM. Anthropometry and biochemical assessments (glycosylated Hb (HbA1c), Vitamin D and PTH) wer...

ba0006p135 | (1) | ICCBH2017

Continuous subcutaneous PTH infusion in autosomal dominant hypocalcaemia

Gevers Evelien , Buck Jacqui , Ashman Neil , Thakker Rajesh , Allgrove Jeremy

Objectives: Autosomal Dominant Hypocalcaemia (ADH) is due to gain-of-function mutations of the CASR resulting in constitutive activation of the GPCR Calcium Sensing Receptor (CaSR) leading to hypercalciuric hypocalcaemia, hypoparathyroidism and occasionally Bartter syndrome type V. Patients usually present with hypocalcaemic seizures at young age. Conventional treatment is with Alfacalcidol and Calcium or PTH injections. We describe a series of five patients with ADH ...

ba0006p136 | (1) | ICCBH2017

Preliminary results for a ramping model of pamidronate administration

Givens Alyssa K , Bachrach Steven , Harcke H Theodore , Kecskemethy Heidi H

Objectives: Examine the effects of a ramped dosage schedule of pamidronate on BMD, fracture rate and location compared to a uniform 5-course regimen. The ramping regimen is intended to alter the tendency for post-treatment fractures to occur at the juncture of pamidronate bands where stress-riser related fractures have been described.Methods: Ten non-ambulatory children (seven females) with neuromuscular disabilities who received IV pamidronate with a ta...

ba0006p197 | (1) | ICCBH2017

Financial burden in families of children with osteogenesis imperfecta (OI)

Murphy Anne , Howard Andrew , Sochett Etienne , Harrington Jennifer

Background: Families of children with Osteogenesis Imperfecta (OI) make costly modifications to their home, lifestyle and employment and incur costs of rehabilitative, preventative and adaptive care for their child. While parents have readily identified that these costs are financially burdensome, the degree of financial burden has not yet been described in families of children with OI.Objectives: To evaluate the out of pocket, OI related expenses (ExpOI...

ba0007oc8 | (1) | ICCBH2019

Bisphosphonate improves hip range of motion and pain but not femoral head sphericity: A multicentre, randomized clinical trial of children with Perthes disease

Jamil Kamal , Zacharin Margaret , Foster Bruce , Donald Geoffrey , Hassall Timothy , Siafarikas Aris , Johnson Michael , Tham Elanie , Whitehead Colin , Gebski Val , Barnes Liz , Cowell Chris , Little David , Munns Craig

Introduction: Perthes disease (PD), idiopathic femoral head avascular necrosis, often results in deformity. The underlying cause is unclear and long-term function is directly related to the roundness of femoral head. Current treatment include mechanical treatments and various surgical procedures, which are therapeutic but can’t prevent collapse. A multicentre, prospective, randomised controlled trial of 12 months zoledronic acid (ZA) in children with PD was conducted. We ...

ba0007oc26 | (1) | ICCBH2019

[18F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages?

Netelenbos Coen , Botman Esmee , Raijmakers Pieter GHM , Lammertsma Adriaan A , Eekhoff Marelise W

Fibrodysplasia ossificans progressiva (FOP) is a rare, autosomal dominant disorder characterized by heterotopic ossification (HO) in muscles, ligaments and tendons. Flare-ups often precede formation of HO, resulting in immobilized joints. Recently, it has been shown that [18F]NaF PET/CT could identify early ossifying disease activity during flare-ups. HO may progress without signs of flare-up, but its underlying physiology is not understood. We wondered whether [18F]NaF PET/CT...